DK2234614T3 - Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel - Google Patents

Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel

Info

Publication number
DK2234614T3
DK2234614T3 DK08863830.9T DK08863830T DK2234614T3 DK 2234614 T3 DK2234614 T3 DK 2234614T3 DK 08863830 T DK08863830 T DK 08863830T DK 2234614 T3 DK2234614 T3 DK 2234614T3
Authority
DK
Denmark
Prior art keywords
ultra
pharmaceutical composition
parenteral administration
blocking agent
receptor blocking
Prior art date
Application number
DK08863830.9T
Other languages
English (en)
Inventor
Rudolf Stefan Widmann
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Application granted granted Critical
Publication of DK2234614T3 publication Critical patent/DK2234614T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08863830.9T 2007-12-21 2008-12-22 Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel DK2234614T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT21072007 2007-12-21
PCT/AT2008/000470 WO2009079679A2 (de) 2007-12-21 2008-12-22 Pharmazeutische zusammensetzung

Publications (1)

Publication Number Publication Date
DK2234614T3 true DK2234614T3 (da) 2013-02-11

Family

ID=40634349

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08863830.9T DK2234614T3 (da) 2007-12-21 2008-12-22 Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel

Country Status (15)

Country Link
US (5) US20100311738A1 (da)
EP (1) EP2234614B1 (da)
JP (1) JP5623288B2 (da)
CN (1) CN101903024A (da)
AU (1) AU2008340179B2 (da)
CA (1) CA2712414C (da)
CY (1) CY1114951T1 (da)
DK (1) DK2234614T3 (da)
ES (1) ES2397126T3 (da)
HR (1) HRP20121045T1 (da)
NZ (1) NZ586200A (da)
PL (1) PL2234614T3 (da)
PT (1) PT2234614E (da)
SI (1) SI2234614T1 (da)
WO (1) WO2009079679A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872953C (en) 2012-05-10 2020-04-07 Aop Orphan Pharmaceuticals Ag Parenteral esmolol formulation
EP2796139A1 (en) * 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004580A1 (en) * 1984-04-09 1985-10-24 American Hospital Supply Corporation Pharmaceutical composition and method for treatment or prophylaxis of cardiac disorders
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
DE4207922A1 (de) 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
CA2150554A1 (en) * 1992-12-02 1994-06-09 Sheng-Wan Tsao Cyclodextrin and polymer based drug delivery system
EP1239864A1 (en) 1999-11-23 2002-09-18 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with n6 -substituted-5'-(n-substituted) carboxamidoadenosines
TWI277414B (en) * 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
WO2003033025A2 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
JP2005530736A (ja) * 2002-04-18 2005-10-13 シーブイ・セラピューティクス・インコーポレイテッド ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
EP1417962A1 (de) 2002-11-06 2004-05-12 AOP Orphan Pharmaceuticals AG Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
CN1827109A (zh) * 2006-04-14 2006-09-06 北京润德康医药技术有限公司 一种以兰洛地尔及其盐为活性成分的冻干粉针制剂及其制备工艺
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol

Also Published As

Publication number Publication date
US20230277674A1 (en) 2023-09-07
WO2009079679A2 (de) 2009-07-02
US11517624B2 (en) 2022-12-06
ES2397126T3 (es) 2013-03-04
AU2008340179A1 (en) 2009-07-02
CA2712414A1 (en) 2009-07-02
US20200323988A1 (en) 2020-10-15
PL2234614T3 (pl) 2013-03-29
SI2234614T1 (sl) 2013-01-31
US20160361422A1 (en) 2016-12-15
US10660964B2 (en) 2020-05-26
CN101903024A (zh) 2010-12-01
US20190046646A1 (en) 2019-02-14
US20100311738A1 (en) 2010-12-09
HRP20121045T1 (hr) 2013-01-31
CY1114951T1 (el) 2016-12-14
JP2011506486A (ja) 2011-03-03
AU2008340179B2 (en) 2014-10-23
EP2234614A2 (de) 2010-10-06
CA2712414C (en) 2016-07-12
JP5623288B2 (ja) 2014-11-12
EP2234614B1 (de) 2012-10-17
NZ586200A (en) 2012-06-29
PT2234614E (pt) 2013-01-25
WO2009079679A3 (de) 2009-11-26

Similar Documents

Publication Publication Date Title
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
DK2322221T3 (da) Farmaceutisk sammensætning til behandling og forebyggelse af cancer
DK3434687T3 (da) Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme
DK2365802T3 (da) Mikrokapsler af rapamycin og anvendelse til behandling af cancer
DK2532366T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK3351630T3 (da) Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2227243T3 (da) Farmaceutisk sammensætning til behandling af obesitet relaterede sygdomme, omfattende et insulinotropisk peptidkonjugat
DK2152290T3 (da) Fremgangsmåder til indgivelse af anti-il-5-antistoffer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
DK3351261T3 (da) Kombinationslægemiddel omfattende IL-12 og et middel til blokering af T-celle-inhibitoriske molekyler i behandlingen af tumorer
DK3395372T3 (da) System til afgivelse af glutathion-baseret medikament
DK2430065T3 (da) Hyperforgrenede polycarbonater til solubilisering af sværtopløselige aktivstoffer
DK2073860T3 (da) Lægemiddelfrigivende coatinger til medicinske indretninger
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
DK2107917T3 (da) Injektionssted til injektion af lægemiddel
DK2445489T3 (da) Sammensætninger til behandling af narkotikamisbrug og forbedring af misbrugsrelateret adfærd
DK3378862T3 (da) Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK2247582T3 (da) Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK2482899T3 (da) Konstruktion til indretning til indgivelse af lægemiddel
DK2569019T3 (da) Sammensætninger, fremgangsmåder og systemer til syntesen og anvendelsen af billeddannelsesmidler
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser